Parkinson’s disease (PD) is the second most common multi-systemic neurodegenerative disorder that is characterized by a broad spectrum of motor and non-motor symptoms (NMSs). Atypical Parkinsonism is a less common group of sporadic, neurodegenerative diseases of the central nervous system but is more severe than PD. The most common forms are multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). Neuroanatomically, NMS may be subdivided into cortical manifestations (psychosis and cognitive impairment), basal ganglia symptoms (impulse control disorders, apathy, and restlessness or akathisia), brainstem symptoms (depression, anxiety, and sleep disorders), as well as the peripheral nervous system disturbances (orthostatic hypotension (OH), constipation, pain) and sensory disturbances. NMS is often overlooked by physicians and dismissed by patients thus making their management difficult, with a major burden for patients and caregivers. Unfortunately, there are very little existing data about NMS, their neurobiology, their potential biomarkers, their monitoring, and their treatment. Moreover, there is growing evidence of the accurate monitoring of NMS by wearable sensors for PD. It is therefore essential that researchers and practitioners comprehensively address the factors related to NMS in order to improve quality of life for PD patients.

Date: 23 December 2024

Time: 6:00 pm CET, 7:00 pm EET, 1:00 am CST.

Webinar ID: 816 1650 2976

Webinar Secretariat: journal.webinar@mdpi.com